Johnson & Johnson (NYSE:JNJ) Stock Price Down 2.2% – Here’s What Happened

Johnson & Johnson (NYSE:JNJ)’s stock price fell 2.2% on Thursday. The stock traded as low as $258.33 and last traded at $258.8060. 8,154,469 shares changed hands during trading, an increase of 2% from the average daily volume of 7,965,625 shares. The stock had previously closed at $264.74.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its JNJ price target to $278 from $263, citing stronger growth prospects and pipeline strength. The firm also increased its estimate for oral psoriasis drug Icotyde’s peak sales to $4.5 billion from $2.4 billion, supporting the long-term earnings outlook. BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
• Positive Sentiment: Analysts remain broadly constructive ahead of JNJ’s October 13 third-quarter report, pointing to favorable Tremfya and Carvykti data. JNJ’s 64-year record of dividend increases and defensive healthcare businesses also continue to support its appeal to income-focused investors. Johnson & Johnson Gears Up for Q3 Earnings
• Neutral Sentiment: A new global survey sponsored by JNJ found that most women do not associate eye-health changes with menopause. The findings could support future education and consumer-health opportunities, but the survey itself is unlikely to materially affect near-term earnings. New Global Survey by Johnson & Johnson
• Negative Sentiment: Investors remain concerned about the anticipated loss of exclusivity and biosimilar erosion for STELARA, which could pressure pharmaceutical revenue. With JNJ’s shares up sharply over the past year and valuation elevated, the upcoming earnings report must demonstrate that newer products can offset that decline. Was the Run in JNJ Stock Hiding in Plain Sight?
• Negative Sentiment: The third-quarter preview calls for approximately $25.31 billion in revenue and $2.48 in adjusted EPS, creating risk of an earnings miss or cautious guidance. Broader dividend comparisons also highlight that patent cliffs and acquisition-related debt remain important risks for large pharmaceutical companies. Johnson & Johnson Q3 Preview

Analyst Ratings Changes

A number of research analysts recently weighed in on JNJ shares. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Citigroup raised their price target on Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research note on Monday, August 3rd. HSBC boosted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $275.87.

Johnson & Johnson Trading Down 2.2%

The company has a 50-day moving average of $266.53 and a 200 day moving average of $248.19. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company has a market cap of $623.70 billion, a PE ratio of 29.99, a price-to-earnings-growth ratio of 2.55 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

Insider Activity

In related news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Silver Coast Investments LLC raised its holdings in Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock valued at $271,000 after buying an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV increased its holdings in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock valued at $1,630,000 after acquiring an additional 39 shares during the last quarter. Triumph Capital Management raised its stake in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock valued at $643,000 after acquiring an additional 39 shares in the last quarter. Denali Advisors LLC lifted its holdings in Johnson & Johnson by 1.2% in the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company’s stock worth $839,000 after purchasing an additional 40 shares during the last quarter. Finally, Beaird Harris Wealth Management LLC boosted its position in Johnson & Johnson by 1.8% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after purchasing an additional 42 shares during the period. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.